10-Q: Surrozen Inc. Reports First Quarter 2025 Financial Results, Highlights Ophthalmology Program Advancements

Sentiment:

Quarterly Report 9 May 2025 4:16 PM

Surrozen Inc. announces its financial results for the first quarter of 2025, focusing on the progress of its ophthalmology programs and recent financing activities.

Capital raiseThe company entered into a securities purchase agreement with certain institutional and accredited investors to issue and sell an aggregate of 15.1 million units in a two-tranche private placement (the 2025 PIPE) at a purchase price of $ 11.60 per share unit and $ 11.5999 per pre-funded warrant unit, for gross proceeds of approximately $ 175.0 million to fund multiple ophthalmology programs through initial Phase 1 safety, tolerability and efficacy studies.Each unit consists of one share of common stock, or pre-funded warrant in lieu thereof, and an accompanying one half of a Series E common stock warrant.The purchase price per unit includes $ 0.0625 for the accompanying one half of a Series E common stock warrant.Each pre-funded warrant has an exercise price of $ 0.0001 per share, is exercisable immediately and will not expire until exercised in full.Each Series E common stock warrant has an exercise price of $ 11.54 per share, is exercisable immediately and expires five years from the date of issuance.At the closing of the first tranche on March 26, 2025, (i) 5.2 million shares of common stock, (ii) pre-funded warrants to purchase up to 1.4 million shares of common stock, and (iii) Series E common stock warrants to purchase up to 3.3 million shares of common stock were issued and sold for aggregate net proceeds of approximately $ 71.3 million, after deducting placement agent fees and other expenses.In the second tranche of the 2025 PIPE, which is contingent upon the public announcement of the receipt of clearance from the U.S. Food and Drug Administration on or prior to October 31, 2026 of the Companys Investigation New Drug Application for SZN-8141, the Company expects to issue a (i) 6.0 million shares of common stock, (ii) pre-funded warrants to purchase up to 2.5 million shares of common stock, and (iii) Series E common stock warrants to purchase up to 4.2 million shares of common stock for aggregate gross proceeds of approximately $ 98.6 million; provided that the second tranche may not occur prior to September 27, 2026.

Worse than expectedThe company's net loss increased significantly in Q1 2025 compared to Q1 2024, indicating a worsening financial performance.

Summary

Surrozen Inc. reported a net loss of $27.0 million for the three months ended March 31, 2025, compared to a net loss of $8.8 million for the same period in 2024.
The company's research service revenue from related parties was $983,000 for the quarter.
Research and development expenses increased to $6.6 million from $5.2 million year-over-year, primarily due to increased manufacturing costs for SZN-043 and consulting fees for ophthalmology programs.
General and administrative expenses remained relatively flat at approximately $4.0 million.
A loss of $2.1 million was recorded due to the amendment and cancellation of warrants.
The company recognized a $71.1 million loss on the execution of the 2025 PIPE (Private Investment in Public Equity).
A gain of $16.3 million was recognized on the change in fair value of the tranche liability.
The company settled a tranche liability for a gain of $1.1 million.
Other income, net, increased by $38.1 million, mainly due to a non-cash change in the fair value of warrant liabilities.
As of March 31, 2025, Surrozen had cash and cash equivalents of $101.6 million and an accumulated deficit of $312.2 million.
The company believes its existing cash and cash equivalents are sufficient to fund operations for at least the next 12 months.
A private placement (2025 PIPE) in March 2025 is expected to provide gross proceeds of $175.0 million to fund ophthalmology programs.
The first tranche of the 2025 PIPE closed on March 26, 2025, resulting in net proceeds of approximately $71.3 million.
The second tranche of the 2025 PIPE is contingent upon FDA clearance of the IND application for SZN-8141.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the company secured significant funding, the increased net loss and discontinuation of a program temper the positive aspects.

Positives

The company successfully completed the first tranche of the 2025 PIPE, securing $71.3 million in net proceeds.
Existing cash and cash equivalents are projected to fund operations for at least the next 12 months.
The company is advancing its ophthalmology programs, including SZN-8141 and SZN-8143, towards clinical studies.
Research service revenue from related parties contributed $983,000 to the company's revenue.
The company recognized a gain of $16.3 million on the change in fair value of the tranche liability.
The company recognized a gain of $1.1 million on the settlement of the tranche liability.

Negatives

The net loss increased significantly to $27.0 million in Q1 2025.
The company incurred a $71.1 million loss on the execution of the 2025 PIPE.
The company discontinued development of SZN-043 in severe alcohol associated hepatitis.
The company recorded a $2.1 million loss due to the amendment and cancellation of warrants.

Risks

The second tranche of the 2025 PIPE is contingent upon FDA clearance of the IND application for SZN-8141, which may not occur.
The company's future success depends on the successful development and commercialization of its ophthalmology programs, which are subject to clinical and regulatory risks.
The company may need to raise additional capital in the future, which may not be available on favorable terms or at all.
The company faces competition from other companies developing treatments for retinal diseases, corneal dystrophy and geographic atrophy.
The company's stock price may be volatile and subject to market fluctuations.

Future Outlook

The company expects to continue to incur losses for the foreseeable future and anticipates the need to raise additional capital to continue to execute its long-range business plan. Management believes that the existing cash and cash equivalents are sufficient for the company to continue operating activities for at least the next 12 months from the date of issuance of its unaudited condensed consolidated financial statements.

Industry Context

Surrozen is operating in the competitive biotechnology industry, focusing on novel treatments for diseases with high unmet needs. The company's focus on ophthalmology and its Wnt therapeutics platform positions it to potentially address significant market opportunities.

Comparison to Industry Standards

It is difficult to compare Surrozen's results directly to industry standards due to its unique Wnt therapeutics platform and focus on ophthalmology.
Comparable companies in the biotechnology sector often have varying stages of clinical development and financial profiles.
The company's cash position and runway are important metrics to compare against other companies of similar size and stage.
The success of the 2025 PIPE and the advancement of its ophthalmology programs will be key factors in assessing Surrozen's performance against industry benchmarks.

Related Party Transactions

The company recognized $1.0 million as research service revenue related party for services rendered to TCGFB, Inc.
The company recognized sublease income of $0.2 million from Nura Bio, Inc.

Stakeholder Impact

Shareholders: Dilution from the 2025 PIPE, but potential for long-term value creation through successful development of ophthalmology programs.
Employees: Continued employment and potential for growth within the company.
Customers: Potential for new and improved treatments for retinal diseases, corneal dystrophy and geographic atrophy.
Suppliers: Continued business relationships with the company.
Creditors: No significant impact.

Next Steps

Continue advancing ophthalmology programs, including SZN-8141 and SZN-8143, towards clinical studies.
Seek FDA clearance for the IND application for SZN-8141 to trigger the second tranche of the 2025 PIPE.
Manage cash burn and explore potential future financing options.
Monitor and adapt to changes in the regulatory landscape.

Key Dates

Date	Description
2015	Surrozen's inception.
2016-03-01	Date of the Stanford License Agreement.
2022-10-01	Execution of the Collaboration and License Agreement (CLA) with Boehringer Ingelheim (BI).
2024	Nomination of SZN-8141 and SZN-8143 as development candidates.
2024-03-31	Date of filing of the Company's Annual Report on Form 10-K.
2024-10-01	Date of the strategic research collaboration with TCGFB, Inc.
2025-03-24	Date of entering into a securities purchase agreement for the 2025 PIPE.
2025-03-26	Closing of the first tranche of the 2025 PIPE.
2025-03-31	End of the quarterly period covered by the report.
2026	Expected filing of an Investigational New Drug application and commencement of clinical studies for SZN-8141.
2026-10-31	Deadline for public announcement of FDA clearance for SZN-8141's IND application for the second tranche of the 2025 PIPE.

Keywords

Surrozen, ophthalmology, retinal diseases, SZN-8141, SZN-8143, SZN-113, PIPE, clinical trials, financial results, warrants, biotechnology

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.